Carbamazepine Toxicity

Etiology

Carbamazepine toxicity occurs following intentional overdose or coadministration of medications that inhibit CYP3A4. Patients receiving antiseizure therapy may be exposed to additional agents that increase interaction risk. Lamotrigine and valproic acid, commonly used in epilepsy and psychiatric disorders, may contribute to the accumulation of carbamazepine’s active metabolite and subsequent toxicity. CYP3A4 inhibitors, including grapefruit juice, amiodarone, and azole antifungals, such as ketoconazole, may increase carbamazepine concentrations and precipitate toxicity. Acute kidney injury is not typically a primary contributor to carbamazepine toxicity, in contrast to other toxic syndromes.

Epidemiology

Carbamazepine overdose is relatively common in the US, with America’s Poison Centers reporting 3,631 documented cases in 2016. Another series of 1,880 cases identified 37% as intentional overdoses, 57% as unintentional overdoses, and 4% as adverse reactions. A retrospective observational study reported that 85.7% of patients with carbamazepine overdose had a history of seizure disorder.[5]

Pathophysiology

Carbamazepine toxicity occurs due to excessive blockade of neuronal and cardiac voltage-gated sodium channels, resulting in dose-dependent central nervous system depression, paradoxical seizures, and myocardial depression with QRS interval prolongation. Antimuscarinic features and hyponatremia may also occur. Typical physical examination findings, including ataxia, nystagmus, delirium, and sedation, are primarily attributable to neuronal sodium channel blockade.

Toxicokinetics

Carbamazepine is highly protein-bound, with a volume of distribution of approximately 0.8 to 1.4 L/kg. Metabolism is dominated by oxidation via CYP3A4 and, to a lesser extent, CYP2C8, resulting in the formation of the active metabolite carbamazepine-10,11-epoxide, which may contribute to toxicity. Additional metabolites have been described, including the dihydroxy derivative of the epoxide. Elimination half-life ranges from 25 to 65 hours following initial dosing. With repeated administration, half-life may decrease significantly due to enzyme autoinduction, characterized by increased expression of metabolic enzymes responsible for carbamazepine clearance. Peak serum concentrations occur between 6 and 24 hours following therapeutic dosing. However, peak concentrations following large overdoses may be delayed up to 72 hours.

Toxicity is classically graded by serum concentration, although symptom thresholds vary between individuals. Disorientation and ataxia occur at serum concentrations of 11 to 15 mg/L. Aggression and hallucinations develop at serum concentrations of 15 to 25 mg/L. Seizures and coma manifest at concentrations exceeding 25 mg/L, particularly in patients with epilepsy.

History and Physical

Symptoms of carbamazepine overdose may be delayed due to slow and erratic gastrointestinal absorption. Carbamazepine primarily exerts toxicity through sodium channel blockade, resulting in neurologic and cardiovascular effects. Nystagmus and ataxia are the most common findings in carbamazepine poisoning. Additional manifestations include dysarthria, vomiting, lethargy, seizures, confusion, and fluctuating levels of consciousness. Cardiac abnormalities, including arrhythmias and QRS interval prolongation, may also be observed. Anticholinergic effects, anemia, rhabdomyolysis, and associated movement disorders have also been reported.[6]

Evaluation

The clinician should perform a careful neurologic and cardiovascular examination and maintain close observation due to the risk of rapid clinical deterioration. Airway, breathing, and circulation require immediate assessment, given the risk of hypotension and potential need for endotracheal intubation. Neurologic examination may reveal nystagmus, dysarthria, ataxia, fluctuating levels of consciousness, or antimuscarinic features.

An initial electrocardiogram (ECG) must be obtained to assess for QRS prolongation, conduction abnormalities, and arrhythmias. ECG monitoring should remain in place until conduction abnormalities resolve. Serial carbamazepine levels may assist in guiding treatment decisions. Additional evaluation should include formulation type, timing, amount ingested, and potential coingestants. Clarification should be obtained regarding the ingestion of syrup, immediate-release tablets, or sustained-release preparations. These factors influence onset, duration, and observation period and are important during consultation with medical toxicology or poison center specialists.

Serum acetaminophen and salicylate concentrations should be obtained after an intentional overdose. Evaluation for coingestion is essential, as mixed ingestions may alter clinical presentation, mask carbamazepine toxicity, or require additional antidotal therapy.[7][8][9]

Treatment / Management

Treatment of carbamazepine toxicity may include supportive care, administration of activated charcoal and sodium bicarbonate, and extracorporeal therapy, such as hemodialysis. Activated charcoal may be beneficial in patients with a protected airway. Multidose activated charcoal (MDAC) may also be considered, which may interrupt the enterohepatic circulation of carbamazepine. Caution is required due to the risk of aspiration in patients with altered mental status or active vomiting. Whole bowel irrigation may be considered only after securing the airway. However, routine use is not generally recommended and may increase the risk of bowel perforation.

Sodium bicarbonate administration should be strongly considered in cases of QRS prolongation and hypotension. Sodium channel–blocking antiseizure medications, particularly phenytoin, should generally be avoided due to potential worsening of conduction abnormalities. Intravenous lipid emulsion therapy has been reported in cases of carbamazepine toxicity. This intervention may facilitate the redistribution of lipophilic drugs from target tissues into an intravascular lipid phase.

Intermittent hemodialysis is appropriate in severe carbamazepine poisoning, particularly because the protein-bound fraction decreases during toxicity. Indications for hemodialysis include refractory seizures, life-threatening dysrhythmias, prolonged coma or respiratory depression that necessitates or is expected to require mechanical ventilation, and sustained or worsening toxicity with rising or persistently elevated serum concentrations despite MDAC administration and supportive care.[10][11][12](A1)

Differential Diagnosis

The differential diagnosis of carbamazepine poisoning should include drug–drug interactions, meningitis, encephalitis, hypothermia, neuroleptic malignant syndrome, and medication-induced dystonic reactions, as well as antidepressant, anticholinergic, lithium, phenytoin, and valproate toxicity. Since many patients receiving carbamazepine have a history of epilepsy, the presence of altered mental status warrants consideration of an active seizure or postictal state.

All antiseizure medications carry a risk of increased suicidality, including carbamazepine. Serum acetaminophen and salicylate concentrations should be obtained to exclude coingestion.

Prognosis

Seizures associated with carbamazepine toxicity is generally managed with benzodiazepine administration. Coma or altered mental status may persist for several days following large acute overdoses. Disposition decisions should be based on clinical symptoms, formulation ingested, ECG findings, and trends in serum concentrations. Patients with persistent symptoms, abnormal ECG findings, or large modified-release ingestions generally require observation or admission. Asymptomatic individuals with normal vital signs and unremarkable examination and ECG findings may be discharged after an appropriate observation period. Patient education is essential to prevent recurrence.

Complications

Complications of carbamazepine toxicity include seizures, coma, respiratory failure, hypotension, cardiac dysrhythmias, aspiration, and rhabdomyolysis. Cardiac and neurologic complications may progress to multisystem failure in severe cases.